Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors Clinical research trials and Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors. Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors clinical trial. Subjects frequently obtain the most expert healthcare possible for their Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "P" Clinical Trials Conditions > Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors

Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors



Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors

For Condition: unspecified adult solid tumor, protocol specific
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Fox Chase Cancer Center
Synopsis: Patient Abstract available in the near future.
Details: OBJECTIVES: I. Determine the maximum tolerated dose of gemcitabine and carboplatin in patients with advanced solid tumors. II. Determine the dose-limiting toxic effects of this regimen in these patients. III. Evaluate the pharmacokinetics and pharmacodynamics of this regimen in these patients. IV. Determine the observed responses in these patients receiving this regimen. PROTOCOL OUTLINE: This is a dose-escalation study of gemcitabine. Patients are stratified according to prior therapy (no prior chemotherapy and/or prior radiotherapy to less than 20% of bone marrow vs prior chemotherapy and/or prior radiotherapy to at least 20% of bone marrow). Patients receive carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 1-3 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose-limiting toxicity. Patients are followed for survival. PROJECTED ACCRUAL: A maximum of 18 patients (9 per stratum) will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed advanced solid tumor for which no standard therapy exists - No untreated brain metastases with evidence of neurologic deterioration or CNS progression --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No more than 2 prior systemic chemotherapy regimens for advanced disease; Prior adjuvant or induction therapy for initial disease allowed; At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or melphalan); No prior combination carboplatin and gemcitabine - Endocrine therapy: Not specified - Radiotherapy: No prior radiotherapy to more than 30% of bone marrow; At least 4 weeks since prior radiotherapy - Surgery: Not specified --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-1 - Life expectancy: More than 3 months - Hematopoietic: Absolute neutrophil count at least 2,000/mm3; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin no greater than 1.5 mg/dL; SGOT no greater than 5 times upper limit of normal - Renal: Creatinine no greater than 1.5 mg/dL - Other: No serious concurrent infection; No other serious concurrent medical illness that would preclude study; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception during and for at least 3 months after study
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
CoreyLanger,  Study Chair,  Fox Chase Cancer Center

Fox Chase Cancer Center
Philadelphia,  Pennsylvania,  19111
United States
 


Additional Information:
Study ID Numbers:  CDR0000068771;  FCCC-97028,NCI-G01-1984
Study Start Date: November 1997
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00021346

Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

2. Methylphenidate in Treating Patients With Melanoma

3. UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

4. Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy

5. Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Related Studies:

Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials

Phase I Study of Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors
Modify your Search

  Other unspecified adult solid tumor, protocol specific Clinical Trials
  Other Pennsylvania Clinical Trials
  Other Philadelphia Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103